Trial Profile
naNO-DENGUE: A Phase I Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T-Cell Priming Peptide Vaccine Against Dengue Virus in Healthy Adults in Switzerland
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs EMX-001 (Primary) ; Genopep
- Indications Dengue; Yellow fever; Zika virus infection
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms naNO-DENGUE
- Sponsors Emergex Vaccines
- 06 Jun 2023 Results presented in an Emergex Vaccines media release.
- 11 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Jul 2022 According to an Emergex Vaccines media release, top line results are expected imminently.